1[1]Klinkoff A. Rheumatology 5: diagnosis and management of inflammatory polyarthritis[J]. CMAJ. 2000,162∶1 833～1 838.
2[2]Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum. 1988,31∶315～324.
3[3]American College of Rheumatology Ad Hoc Committee on Clinical Guidelines for the management of rheumatoid arthritis[J]. Arthritis Rheum. 1996,39∶713～722.
4[4]Simon L. DMARDS in the treatment of rheumatoid arthritis: current agents and future developments[J]. Int J Clin Pract. 2000, 54∶243～249.
5[5]Lanas A. Clinical experience with cyc- looxygenase-2 inhibitors. Rheumatology. 2002,41 Supp 1∶16～22.
6[6]Buffum M, Buffum JC. Nonsteroidal anti-inflammatory drugs in the elderly[J]. Pain Manag Nurs. 2000,1(2)∶40～50.
7[7]Infante R, Lahita RG. New disease-modifying and anti-inflammatory drugs[J]. Geriatrics. 2000,55∶30～40.
8[8]Maini R, St Clair EW, Breedvelt F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial[J], ATTRACT study group. Lancet. 1999,354∶1 932～1 939.
9[9]Madigan A, FitzGerald O. Multidisciplinary patient care in rheumatoid arthritis: evolving concepts in nursing practice[J]. Baillieres Best Pract Res Clin Rheumatol.1999, 13(4)∶661～74.
10[10]Moder KG. New medications for use in patients with rheumatoid arthritis[J]. Ann Allergy Asthma lmmunol. 2000,84∶280～287.
